RT Journal Article
SR Electronic
T1 Investigating spatial variability in COVID-19 pandemic severity across 19 geographic areas, Spain, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.14.20065524
DO 10.1101/2020.04.14.20065524
A1 Dahal, Sushma
A1 Mizumoto, Kenji
A1 Rothenberg, Richard
A1 Chowell, Gerardo
YR 2020
UL http://medrxiv.org/content/early/2020/07/04/2020.04.14.20065524.abstract
AB Introduction Spain has been disproportionately affected by the COVID-19 pandemic, ranking fifth in the world in terms of both total cases and total deaths due to COVID-19 as of May 20, 2020. Here we derived estimates of pandemic severity and assessed its relationship with socio-demographic and healthcare factors.Methods We retrieved the daily cumulative numbers of laboratory-confirmed COVID-19 cases and deaths in Spain from February 20, 2020 to May 20, 2020. We used statistical methods to estimate the time-delay adjusted case fatality risk (aCFR) for 17 autonomous communities and 2 autonomous cities of Spain. We then assessed how transmission and sociodemographic variables were associated with the aCFR across areas using multivariate regression analysis.Results We estimated the highest aCFR for Madrid (25.9%) and the average aCFR in Spain (18.2%). Our multivariate regression analysis revealed three statistically significant predictor variables: population size, population density, and the unemployment rate.Conclusions The estimated aCFR for 10 autonomous communities/cities in Spain are significantly higher than those previously estimated for other geographic regions including China and Korea. Our results suggest that public health interventions focused on densely populated areas and low socioeconomic groups can ameliorate the mortality burden of the COVID-19 pandemic in Spain.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKM acknowledges support from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 20H03940, and from the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan.GC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program; UK Biotechnology and Biological Sciences Research Council grant BB/M008894/1.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.